Helena Norberg1,2, Veronica Pranic1, Ellinor Bergdahl1, Krister Lindmark3. 1. Department of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden. 2. Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden. 3. Department of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden. krister.lindmark@umu.se.
Abstract
PURPOSE: The aims of this study were to examine sex differences in a heart failure population with regards to treatment and patient characteristics and to investigate the impact of sex on achieved doses of heart failure medications. METHODS AND RESULTS: A total of 1924 patients with heart failure in a regional hospital were analysed, 622 patients had ejection fraction ≤ 40% of which 30% were women. In patients with reduced ejection fraction, women were older (79 ± 11 vs. 74 ± 12 years, P < 0.001), had lower body weight (70 ± 17 vs. 86 ± 18 kg, P < 0.001), lower estimated glomerular filtration rate (eGFR) (49 ± 24 vs. 71 ± 30 ml/min, P < 0.001) and received lower doses of heart failure medications than men. Multivariable linear regression on patients with reduced ejection fraction showed that sex was not associated with achieved dose of any heart failure medication. For angiotensin-converting enzyme inhibitors and angiotensin receptor blockers associated factors were eGFR, systolic blood pressure, age, ejection fraction, and heart rate. For beta-blockers associated factors were body weight, atrial fibrillation and age. For mineralocorticoid receptor antagonists associated factors were eGFR, serum potassium, age, systolic blood pressure, ejection fraction and heart rate. CONCLUSION: Women with heart failure and reduced ejection fraction were prescribed lower doses of heart failure medications, were older, had worse renal function, and lower body weight than men. Sex was not independently associated with achieved doses of heart failure medications, instead age, renal function and body weight explained the differences in treatment.
PURPOSE: The aims of this study were to examine sex differences in a heart failure population with regards to treatment and patient characteristics and to investigate the impact of sex on achieved doses of heart failure medications. METHODS AND RESULTS: A total of 1924 patients with heart failure in a regional hospital were analysed, 622 patients had ejection fraction ≤ 40% of which 30% were women. In patients with reduced ejection fraction, women were older (79 ± 11 vs. 74 ± 12 years, P < 0.001), had lower body weight (70 ± 17 vs. 86 ± 18 kg, P < 0.001), lower estimated glomerular filtration rate (eGFR) (49 ± 24 vs. 71 ± 30 ml/min, P < 0.001) and received lower doses of heart failure medications than men. Multivariable linear regression on patients with reduced ejection fraction showed that sex was not associated with achieved dose of any heart failure medication. For angiotensin-converting enzyme inhibitors and angiotensin receptor blockers associated factors were eGFR, systolic blood pressure, age, ejection fraction, and heart rate. For beta-blockers associated factors were body weight, atrial fibrillation and age. For mineralocorticoid receptor antagonists associated factors were eGFR, serum potassium, age, systolic blood pressure, ejection fraction and heart rate. CONCLUSION:Women with heart failure and reduced ejection fraction were prescribed lower doses of heart failure medications, were older, had worse renal function, and lower body weight than men. Sex was not independently associated with achieved doses of heart failure medications, instead age, renal function and body weight explained the differences in treatment.
Entities:
Keywords:
HFrEF; Heart failure; Sex differences; Target dose
Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Pooja Dewan; Rasmus Rørth; Pardeep S Jhund; Li Shen; Valeria Raparelli; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Ulrik M Mogensen; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray Journal: J Am Coll Cardiol Date: 2019-01-08 Impact factor: 24.094
Authors: Pierpaolo Pellicori; Alessia Urbinati; Parin Shah; Alexandra MacNamara; Syed Kazmi; Riet Dierckx; Jufen Zhang; John G F Cleland; Andrew L Clark Journal: Eur J Heart Fail Date: 2017-02-27 Impact factor: 15.534
Authors: P de Groote; R Isnard; P Assyag; P Clerson; A Ducardonnet; M Galinier; G Jondeau; I Leurs; J-F Thébaut; M Komajda Journal: Eur J Heart Fail Date: 2007-12 Impact factor: 15.534
Authors: Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Michael Fu; Ola Vedin; Bodil Svennblad; Erik Lampa; Daniel Johansson; Ulf Dahlström; Krister Lindmark; Peter Vasko; Anna Lundberg; Madlaina Costa-Scharplatz; Lars H Lund Journal: ESC Heart Fail Date: 2020-09-03
Authors: Anyuli Gracia Gutiérrez; Beatriz Poblador-Plou; Alexandra Prados-Torres; Fernando J Ruiz Laiglesia; Antonio Gimeno-Miguel Journal: Int J Environ Res Public Health Date: 2020-03-23 Impact factor: 3.390